Without the protection of HSP90α, BCR/ABL might degrade, which leads to the downregulation of the expression of BCR/ABL and its downstream molecules and reduced oncogenic properties of CML cells. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.